X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GLENMARK PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GLENMARK PHARMA ALEMBIC LTD/
GLENMARK PHARMA
 
P/E (TTM) x 51.9 19.8 262.3% View Chart
P/BV x 2.2 3.5 64.2% View Chart
Dividend Yield % 0.5 0.3 151.3%  

Financials

 ALEMBIC LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
GLENMARK PHARMA
Mar-18
ALEMBIC LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs72930 7.7%   
Low Rs34517 6.6%   
Sales per share (Unadj.) Rs4.7322.6 1.5%  
Earnings per share (Unadj.) Rs6.128.5 21.4%  
Cash flow per share (Unadj.) Rs6.239.2 15.9%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.3 136.7%  
Book value per share (Unadj.) Rs40.7183.0 22.2%  
Shares outstanding (eoy) m267.03282.17 94.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.2 502.1%   
Avg P/E ratio x8.725.4 34.2%  
P/CF ratio (eoy) x8.518.5 45.9%  
Price / Book Value ratio x1.34.0 32.9%  
Dividend payout %3.37.0 46.7%   
Avg Mkt Cap Rs m14,139204,206 6.9%   
No. of employees `000NA13.7 0.0%   
Total wages/salary Rs m20718,718 1.1%   
Avg. sales/employee Rs ThNM6,636.8-  
Avg. wages/employee Rs ThNM1,364.7-  
Avg. net profit/employee Rs ThNM586.1-  
INCOME DATA
Net Sales Rs m1,25591,031 1.4%  
Other income Rs m370914 40.5%   
Total revenues Rs m1,62591,945 1.8%   
Gross profit Rs m11116,154 0.7%  
Depreciation Rs m383,019 1.3%   
Interest Rs m22,856 0.1%   
Profit before tax Rs m44211,193 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m243,155 0.8%   
Profit after tax Rs m1,6308,039 20.3%  
Gross profit margin %8.917.7 49.9%  
Effective tax rate %5.428.2 19.2%   
Net profit margin %129.88.8 1,470.4%  
BALANCE SHEET DATA
Current assets Rs m1,86769,887 2.7%   
Current liabilities Rs m59132,879 1.8%   
Net working cap to sales %101.640.7 250.0%  
Current ratio x3.22.1 148.6%  
Inventory Days Days9481 115.8%  
Debtors Days Days7493 78.7%  
Net fixed assets Rs m1,79128,892 6.2%   
Share capital Rs m534282 189.3%   
"Free" reserves Rs m10,32451,353 20.1%   
Net worth Rs m10,85851,635 21.0%   
Long term debt Rs m4141,418 0.1%   
Total assets Rs m11,591125,954 9.2%  
Interest coverage x260.94.9 5,302.9%   
Debt to equity ratio x00.8 0.5%  
Sales to assets ratio x0.10.7 15.0%   
Return on assets %14.18.6 162.7%  
Return on equity %15.015.6 96.4%  
Return on capital %15.215.1 100.6%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1936,317 0.1%   
Fx outflow Rs m2649,720 2.7%   
Net fx Rs m-24426,598 -0.9%   
CASH FLOW
From Operations Rs m23616,481 1.4%  
From Investments Rs m-224-10,133 2.2%  
From Financial Activity Rs m-27-4,685 0.6%  
Net Cashflow Rs m-151,770 -0.8%  

Share Holding

Indian Promoters % 64.0 48.3 132.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.9%  
FIIs % 9.7 34.4 28.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 56,727 96.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Dec 12, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS